07:00 , Oct 24, 2011 |  BioCentury  |  Product Development

Alzheimer's rewind

A string of Phase II and III failures in Alzheimer's disease has prompted companies to look for new targets beyond the well-known players in the core mechanism of AD - the production and accumulation of...
07:00 , Sep 16, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) g-Secretase activating protein (GSAP; PION) In vitro and mouse studies suggest inhibiting GSAP could help treat AD. In cell culture, RNAi knockdown...
07:00 , Sep 16, 2010 |  BC Innovations  |  Targets & Mechanisms

Introducing GSAP

Following a lead provided by Gleevec , a team of U.S. researchers from The Rockefeller University and Intra-Cellular Therapies Inc. has identified a new regulatory protein, g-secretase activating protein, that activates g-secretase, a key Alzheimer's...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

pION Inc., Tecan sales and marketing update

The companies launched their PAMPA Explorer, a manual system for drug permeability screening. The system uses TECN's Infinite M200 plate and pION's Double-Sink parallel artificial membrane permeability assay (PAMPA). pION Inc. , Woburn, Mass.  ...